Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: A controlled laboratory study

Critical Care

Volumn 14, Issue 2, 2010, Pages

  Schouten, Marcel ^a   van der Sluijs, Koenraad F ^a   Gerlitz, Bruce ^b   Grinnell, Brian W ^b   Roelofs, Joris J T H ^a   Levi, Marcel M ^a   van 't Veer, Cornelis ^a   Poll, Tom V D ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; FIBRIN DEGRADATION PRODUCT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MYELOPEROXIDASE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA; ANTICOAGULANT AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CAUSE OF DEATH; CONTROLLED STUDY; DRUG INHIBITION; FIBRINOLYSIS; INFLAMMATION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LETHAL DOSE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN; ANIMAL; BLOOD; BLOOD CLOTTING; C57BL MOUSE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; LUNG; METABOLISM; ORTHOMYXOVIRUS INFECTION; PATHOGENICITY; PATHOPHYSIOLOGY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DOWN-REGULATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN C; RECOMBINANT PROTEINS; VIRAL LOAD;

EID: 77950631622     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8964     Document Type: Article

References (49)

1. Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006, 163:181-187. 10.1093/aje/kwj024, 16319291.
2. Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, Peiris JS, Guan Y. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci USA 2009, 106:11709-11712. 10.1073/pnas.0904991106, 2709671, 19597152.
3. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quinones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA. Pneumonia and respiratory failure from swine-origin Influenza. A (H1N1) in Mexico. N Engl J Med 2009, 361:680-689. 10.1056/NEJMoa0904252, 19564631.
4. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351:2611-2618. 10.1056/NEJMoa041747, 15602021.
5. Blanquer J, Blanquer R, Borras R, Nauffal D, Morales P, Menendez R, Subias I, Herrero L, Redon J, Pascual J. Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study. Thorax 1991, 46:508-511. 10.1136/thx.46.7.508, 463249, 1908605.
6. Nauffal D, Menendez R, Morales P, Gonzalez-Granda D, Blanquer J, Blanquer R, Borras R, Millan E, Subias I, Aycart MD. Community viral pneumonia in the adult population: a prospective multicenter study of 62 cases. The Pneumonia Study Group of the Community of Valencia. Rev Clin Esp 1990, 187:229-232.
7. Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, Cheng SH, Wang JT, Liu YC, Cheng YW, Chen ST, Fung CP, Chuang YC, Cheng HP, Lu DC, Liu CJ, Huang IW, Hung CL, Hsiao CF, Ho M. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005, 99:1079-1086. 10.1016/j.rmed.2005.02.026, 16085210.
8. Beigel JH. Influenza. Crit Care Med 2008, 36:2660-2666. 10.1097/CCM.0b013e318180b039, 18679129.
9. Schouten M, Wiersinga WJ, Levi M, Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008, 83:536-545. 10.1189/jlb.0607373, 18032692.
10. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia - Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000, 161:454-462.
11. Choi G, Schultz MJ, Levi M, Poll T, Millo JL, Garrard CS. Protein C in pneumonia. Thorax 2005, 60:705-706. 10.1136/thx.2004.037341, 1747500, 16061717.
12. Rijneveld AW, Florquin S, Bresser P, Levi M, De Waard V, Lijnen R, Zee JS, Speelman P, Carmeliet P, Poll T. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003, 102:934-939. 10.1182/blood-2003-01-0227, 12702502.
13. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007, 109:3161-3172. 10.1182/blood-2006-09-003004, 17110453.
14. Macias WL, Nelson DR. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32:S223-S228. 10.1097/01.CCM.0000126120.49367.AC, 15118522.
15. Vail GM, Xie YJ, Haney DJ, Barnes CJ. Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. Infection 2009, 37:358-364. 10.1007/s15010-008-8128-6, 19169631.
16. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
17. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SCB, Dhainaut JF. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005, 33:952-961. 10.1097/01.CCM.0000162381.24074.D7, 15891319.
18. Watanabe T, Yoshikawa H, Abe Y, Yamazaki S, Uehara Y, Abe T. Renal involvement in children with influenza A virus infection. Pediatr Nephrol 2003, 18:541-544.
19. Keller TT, Sluijs KF, De Kruif MD, Gerdes VEA, Meijers JCM, Florquin S, Poll T, Van Gorp ECM, Brandjes DPM, Büller HR, Levi M. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006, 99:1261-1269. 10.1161/01.RES.0000250834.29108.1a, 17068293.
20. Van Zoelen MA, Sluijs KF, Achouiti A, Florquin S, Braun-Pater JM, Yang H, Nawroth PP, Tracey KJ, Bierhaus A, Poll T. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009, 391:265-273. 10.1016/j.virol.2009.05.032, 19592063.
21. Sluijs KF, Van Elden LJ, Arens R, Nijhuis M, Schuurman R, Florquin S, Kwakkel J, Akira S, Jansen HM, Lutter R, Poll T. Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. Immunology 2005, 114:112-120. 10.1111/j.1365-2567.2004.02000.x, 1782065, 15606801.
22. Berg DT, Gerlitz B, Shang J, Smith T, Santa P, Richardson MA, Kurz KD, Grinnell BW, Mace K, Jones BE. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci USA 2003, 100:4423-4428. 10.1073/pnas.0736918100, 153571, 12671072.
23. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005, 3:1351-1359. 10.1111/j.1538-7836.2005.01385.x, 15978090.
24. Elms MJ, Bundesen PG, Rowbury D, Goodall S, Wakeham N, Rowell JA, Hillyard CJ, Rylatt DB. Automated-determination of cross-linked fibrin derivatives in plasma. Blood Coagul Fibrinolysis 1993, 4:159-164.
25. Verheijen JH, Wijngaards G, Kluft C, Chang G, Mullaart E, Preston FE. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982, 48:266-269.
26. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen-activator in human-plasma. Thromb Haemost 1984, 51:392-395.
27. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002, 168:3507-3511.
28. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79:918-925. 10.1172/JCI112902, 424237, 3102560.
29. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996, 88:2093-2100.
30. Taylor FB, Lockhart MS. Whole-blood clot lysis - In vitro modulation by activated protein C. Thromb Res 1985, 37:639-649. 10.1016/0049-3848(85)90193-8, 3838829.
31. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996, 87:642-647.
32. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997, 272:L197-L202.
33. Suzuki K, Gabazza C, Hayashi T, Kamada H, Adachi Y, Taguchi O. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004, 32:S262-S265. 10.1097/01.CCM.0000129668.96935.A8, 15118528.
34. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, Poll T. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004, 59:130-135. 10.1136/thorax.2003.013888, 1746934, 14760153.
35. Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000, 83:853-860.
36. Choi G, Schultz MJ, Van Till JW, Bresser P, Zee JS, Boermeester MA, Levi M, Poll T. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004, 24:786-789. 10.1183/09031936.04.00140703, 15516673.
37. Rijneveld AW, Weijer S, Bresser P, Florquin S, Vlasuk GP, Rote WE, Spek CA, Reitsma PH, Zee JS, Levi M, Poll T. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006, 34:1725-1730. 10.1097/01.CCM.0000218807.20570.C2, 16625114.
38. Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol 2008, 15:481-486. 10.1097/MOH.0b013e328304b3e3, 18695371.
39. Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005, 171:1125-1128. 10.1164/rccm.200411-1483OC, 2718442, 15750041.
40. Choi G, Vlaar APJ, Schouten M, Van't Veer C, Poll T. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007, 30:423-428. 10.1183/09031936.00165606, 17537762.
41. Choi G, Hofstra JJH, Roelofs JJTH, Florquin S, Bresser P, Levi M, Poll T, Schultz MJ. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007, 35:1362-1368. 10.1097/01.CCM.0000261888.32654.6D, 17414732.
42. Choi G, Hofstra JJH, Roelofs JJTH, Rijneveld AW, Bresser P, Zee JS, Florquin S, Poll T, Levi M, Schultz MJ. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008, 36:204-210. 10.1097/01.CCM.0000292012.87482.F4, 18090375.
43. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, O'Brien J, Gruber M, Zarini S, Murphy RC, Kuhn K, Richter D, Kast KR, Abraham E. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004, 104:3878-3885. 10.1182/blood-2004-06-2140, 15339848.
44. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, O'Neill L, Kelleher D, Schwarz HP, Smith OP. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappa B (NF-kappa B) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000, 110:130-134. 10.1046/j.1365-2141.2000.02128.x, 10930989.
45. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004, 21:222-229. 10.1097/01.shk.0000116778.27924.79, 14770034.
46. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007, 204:2439-2448. 10.1084/jem.20070404, 2118455, 17893198.
47. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernandez JA, Yang XV, Riewald M, Weiler H, Ruggeri ZM, Griffin JH. Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant. Blood 2009, 113:5970-5978. 10.1182/blood-2008-10-183327, 19244160.
48. Macias WL, Dhainaut JF, Yan SCB, Helterbrand JD, Seger M, Johnson G, Small DS. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002, 72:391-402. 10.1067/mcp.2002.128148, 12386641.
49. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW. Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009, 20:267-277. 10.1681/ASN.2008030294, 2637057, 19092124.